These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38061425)

  • 1. Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study.
    Durán-Martínez M; Azriel S; Doulatram-Gamgaram VK; Moreno-Pérez Ó; Pinés-Corrales PJ; Tejera-Pérez C; Merino-Torres JF; Brito-Sanfiel M; Chico A; Marco A; García-Fernández E; Martínez-Montoro JI;
    Diabetes Metab; 2024 Jan; 50(1):101501. PubMed ID: 38061425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report.
    Tian Y; Hu W; Yan Q; Feng B
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241059
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
    Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
    Front Public Health; 2022; 10():990281. PubMed ID: 36091534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
    Araki E; Mathieu C; Shiraiwa T; Maeda H; Ikeda H; Thoren F; Arya N; Asano M; Iqbal N
    Diabetes Obes Metab; 2021 Jul; 23(7):1496-1504. PubMed ID: 33620762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
    Li Y; Li H; Dong L; Lin D; Xu L; Lou P; Zang D; Wang K; Ma L
    Front Endocrinol (Lausanne); 2022; 13():923376. PubMed ID: 35872994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
    Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L
    Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
    Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
    J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
    Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
    Mathieu C; Dandona P; Birkenfeld AL; Hansen TK; Iqbal N; Xu J; Repetto E; Scheerer MF; Thoren F; Phillip M
    Diabetes Obes Metab; 2020 Nov; 22(11):2151-2160. PubMed ID: 32691513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy.
    Chou WY; Li YR; Chan WK; Chen ST
    Biomed J; 2018 Dec; 41(6):348-355. PubMed ID: 30709576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
    Dandona P; Mathieu C; Phillip M; Hansen L; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2018 Dec; 41(12):2552-2559. PubMed ID: 30352894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous glucose monitoring systems for type 1 diabetes mellitus.
    Langendam M; Luijf YM; Hooft L; Devries JH; Mudde AH; Scholten RJ
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD008101. PubMed ID: 22258980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort.
    Hironaka J; Okada H; Hamaguchi M; Sakai K; Minamida M; Kondo Y; Hashimoto Y; Kitagawa N; Yano M; Yamazaki M; Hasegawa G; Horiguchi G; Teramukai S; Fukui M
    Diabetes Res Clin Pract; 2023 Aug; 202():110794. PubMed ID: 37336391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.